LONDON, November 26 /PRNewswire/ -- Daval International Limited, a UK private company, announces MHRA and IRB (Ethics Committee) approval of a London based Phase IIB trial of AIMSPRO(R), its hyperimmune caprine serum derivative.
This double-blind placebo-controlled cross-over study will seek to detect a beneficial effect on bladder function in patients with Secondary Progressive Multiple Sclerosis, following open-label observations over several years in a number of informed consent, "compassionate basis" patients.
AIMSPRO has an "export only" listing on the Australian Registry of Therapeutic Goods and a TGA Orphan Status Designation for the treatment of Krabbe's disease. An IND application is being lodged for a further MS trial in the United States.
AIMSPRO is a frozen medication, given as a 1ml sub-cutaneous injection every 4 days. It is believed to have a pronounced and sustained anti-inflammatory action with an associated, novel effect of lowering sodium channel triggering voltages in nerve fibres. MHRA applications for two further clinical trials are to be lodged within the next 3months.
Daval International Ltd. has recently been accepted as a member of the Association of the British Pharmaceutical Industry. "APBI"
Daval International Limited
Daval International Limited is a privately owned British pharmaceutical company, which, since 2001, has been developing an immunologically active human and veterinary medication derived from goat serum. Some 20.000 doses of Aimspro have been administered, mainly to human subjects with multiple sclerosis, with an excellent safety and tolerance profile.
CONTACT: Enquiries to:- email@example.com, Dr.Bryan Youl,
+44(0)779-352-6096; Brian Quick, +44(0)776-482-8114